This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics


  • 00
  • 00
  • 00
  • 00
May 7-10, 2023 | In-Person + Digital
San Diego, CA, USAManchester Grand Hyatt San Diego

Lukas Scheibler, PhD
Chief Innovation Officer at Apellis


Dr. Scheibler joined Apellis in April 2018 as executive vice president for research and translational medicine. In this role, he is responsible for creating and managing all preclinical research projects and advancing them into clinical development to establish proof of concept. Dr. Scheibler is an R&D professional with in-depth experience in drug development. He most recently was head of R&D at Acucela (a Seattle-based startup) and had a 13-year career in research and development, business development, and clinical development at Novartis. He holds a PhD degree from the University of Lausanne, Switzerland, and had postdoctoral training at Harvard Medical School.

Agenda Sessions

  • The New Frontier in Complement Medicines